Alector Company
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders.
Investors
Technology:
Gene therapy
Industry:
Longevity
Headquarters:
United States
Founded Date:
01.01.2013
Employees Number:
101-250
Funding Status:
IPO
Investors Number:
20
Total Funding:
$195 M
Estimated Revenue:
$10M to $50M
Last Funding Date:
25 07 18
Last Funding Type:
Series E
Register and Claim Ownership